Properties of pervanadate and permolybdate. Connexin43, phosphatase inhibition, and thiol reactivity as model systems.
Pervanadate and permolybdate are irreversible protein-tyrosine phosphatase inhibitors, with IC50 values of 0.3 and 20 microM, respectively, in intact cells. Maximal inhibition was obtained within 1 min at higher concentrations of the compounds. They induced prominent changes in the phosphorylation status of the gap junction protein, connexin43. These effects were utilized as model systems to assess the stability and inactivation of the compounds. Although the concentrated stock solutions were relatively stable, the diluted compounds were unstable. The biological activity had decreased to 20-30% after 6 h of incubation in a phosphate buffer, 1 h in phosphate buffer with 10% fetal calf serum, and 1-3 minutes in culture medium. Thiols reacted rapidly with the compounds and inactivated them (initial reaction rates with cysteine: permolybdate > pervanadate > H2O2). Catalase inactivated the compounds, and permolybdate was the more sensitive. The cells inactivated permolybdate faster than pervanadate. Cellular inactivation of permolybdate, and to a lesser degree pervanadate, appeared to be partly dependent on catalase and thiols. However, a general decrease in cellular thiols was not the mediator of the biological effects of pervanadate or permolybdate. Mathematical modeling of the thiol reactivity suggested that monoperoxovanadate at maximum could possess 20% of the biological activity of diperoxovanadate.
Mikalsen
S O
SO
Department of Environmental and Occupational Cancer, Institute for Cancer Research, The Norwegian Radium Hospital, N-0310 Oslo, Norway. s.o.mikalsen@labmed.uio.no
Kaalhus
O
O
D000818:Animals; D002374:Catalase / Q000378:metabolism; D002478:Cells, Cultured; D018031:Connexin 43 / Q000037:antagonists & inhibitors*; D006224:Cricetinae; D004305:Dose-Response Relationship, Drug; D004355:Drug Stability; D004622:Embryo, Mammalian; D004791:Enzyme Inhibitors / Q000138:chemical synthesis / Q000737:chemistry / Q000494:pharmacology*; D005033:Ethylmaleimide / Q000494:pharmacology; D017629:Gap Junctions / Q000187:drug effects / Q000502:physiology; D007700:Kinetics; D008647:Mesocricetus; D008956:Models, Chemical; D008982:Molybdenum / Q000737:chemistry / Q000494:pharmacology*; D010087:Oxides / Q000737:chemistry / Q000494:pharmacology*; D010766:Phosphorylation; D017027:Protein Tyrosine Phosphatases / Q000037:antagonists & inhibitors*; D013329:Structure-Activity Relationship; D013438:Sulfhydryl Compounds / Q000737:chemistry* / Q000494:pharmacology; D014638:Vanadates / Q000138:chemical synthesis / Q000737:chemistry / Q000494:pharmacology*
D018031:Connexin 43; D004791:Enzyme Inhibitors; D010087:Oxides; D013438:Sulfhydryl Compounds; C111901:permolybdate; C076715:pervanadate; D014638:Vanadates; D008982:Molybdenum; D002374:Catalase; D017027:Protein Tyrosine Phosphatases; D005033:Ethylmaleimide